AXSM 241220 92.50P (AXSM241220P92500) Stock Options, News & Quotes

US OptionsDetailed Quotes

AXSM241220P92500

Watchlist

2.50
-3.50-58.33%

15min DelayClose Dec 20 16:00 ET

2.50High2.00Low

Intraday

5D
Daily

News

Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Announces Target Price $124
Moomoo NewsDec 20 14:31 ET · Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Hims & Hers Health (HIMS), Zymeworks (ZYME) and Axsome Therapeutics (AXSM)
TipRanksDec 16 01:30 ET · Ratings
Positive Outlook for Axsome Therapeutics: Buy Rating Backed by Promising AXS-05 Prospects
TipRanksDec 10 01:37 ET · Ratings
Axsome Therapeutics: Promising Growth Trajectory Justifies Buy Rating Amidst Auvelity's Commercial Success
TipRanksDec 7 10:35 ET · Ratings
Express News | Axsome Therapeutics Inc : Mizuho Raises Target Price to $124 From $106
ReutersDec 3 05:35 ET
Morgan Stanley Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $125
Moomoo NewsNov 30 08:32 ET · Ratings

Comments

Clintzilla

Oct 12 14:13

$Axsome Therapeutics (AXSM.US)$ wonder what the insitutional ownership was when it went from 2 to 110 lol

Vincenttpc

Sep 25 08:07

$Axsome Therapeutics (AXSM.US)$ why the sudden drop?

Meltyy

Mar 18 03:21

FDA Development Paths

$Pfizer (PFE.US)$ $Novo-Nordisk A/S (NVO.US)$ $Axsome Therapeutics (AXSM.US)$ $Macrogenics (MGNX.US)$
1️⃣ Standard Designation: Standard designation is the typical pathway for drug development, involving preclinical studies and three phases of clinical trials to assess safety and efficacy thoroughly.
2️⃣ Orphan Designation: Reserved for drugs targeting rare diseases, this designation offers incentives like tax credits and marketing exclusivity to encourage development for underserved ...

Meltyy

Mar 4 03:54

🎯 Ph 3 readouts in Q1 2024...

$Pfizer (PFE.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3
$Atea Pharmaceuticals (AVIR.US)$ Phase 3
$Crinetics (CRNX.US)$ Phase 3
$Axsome Therapeutics (AXSM.US)$ Phase 3
$ROCHE HOLDING AG (RHHBY.US)$ Phase 3
$ACADIA Pharmaceuticals (ACAD.US)$ Phase 3
$Sellas Life Sciences (SLS.US)$ Phase 3
$Aquestive Therapeutics (AQST.US)$ Phase 3
$Jaguar Health (JAGX.US)$ Phase 3
$Novocure (NVCR.US)$ Phase 3
$Johnson & Johnson (JNJ.US)$ Phase 3

Meltyy

Feb 26 00:34

4 Bio Readouts To Watch This Qtr

1. $Annovis Bio (ANVS.US)$
• Ph 3 data (also Ph 2/3 in AD).
• Buntanetap for Parkinson’s Disease.
• Exp Jan '24 but delayed (est this qtr).
2. $Axsome Therapeutics (AXSM.US)$
• Ph 3 data (SYMPHONY).
• AXS-12 for Narcolepsy.
• AXS-12 has Orphan Drug Designation.
3. $G1 Therapeutics (GTHX.US)$
• Ph 3 Overall Survival (OS) data.
• Trilaciclib (combo) for breast cancer (mTNBC).
• DMC recommended continuation earlier in Feb.
4. $Crinetics (CRNX.US)$
• Ph 3 data (PATHFND...